Inari Medical Reports Preliminary Unaudited Revenue For Q4 Of 2023 Of At Least $132M, Up 22% Y/Y Versus Consensus Of $130.98M, With FY23 Preliminary Unaudited Revenue Of At Least $493.5M, Up 29% Y/Y Versus Consensus Of $492.61M
Portfolio Pulse from Benzinga Newsdesk
Inari Medical announced preliminary unaudited revenue for Q4 2023 of at least $132M, a 22% increase year-over-year, surpassing the consensus estimate of $130.98M. The company also reported preliminary unaudited revenue for FY23 of at least $493.5M, a 29% increase year-over-year, slightly above the consensus estimate of $492.61M.
January 09, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inari Medical's Q4 2023 revenue exceeded expectations with a 22% Y/Y increase, and FY23 revenue also saw a 29% Y/Y increase, slightly beating consensus estimates.
Inari Medical's reported revenue growth for both Q4 and FY23 is likely to be viewed positively by investors, as the company has not only shown strong year-over-year growth but also exceeded consensus estimates. This positive financial performance is expected to instill confidence in the company's growth trajectory and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100